Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GBT021601.

Locations

915 United States sites

150 Nigeria sites

50 Kenya sites

28 Lebanon sites

Age

6 Months - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

1441 United States site

846 India sites

392 United Kingdom sites

287 Canada sites

259 Italy sites

218 Turkey sites

203 Greece sites

162 France sites

157 Spain sites

79 South Africa sites

22 Lebanon sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.

Locations

885 United States sites

143 Canada sites

89 Lebanon sites

Age

12 Years - 65 Years

Phase

Phase 2

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

3505 United States sites

472 United Kingdom sites

330 Spain sites

329 France sites

263 Italy sites

261 Greece site

198 Canada sites

136 Oman sites

132 Germany sites

131 Lebanon site

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

407 United States sites

195 Belgium sites

195 Brazil sites

195 Turkey sites

130 France sites

130 Italy sites

130 Lebanon sites

65 Colombia sites

65 Oman sites

65 Germany sites

65 Spain sites

Age

> 6 Months Years

Phase

Phase 4

LEARN MORE
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.

Locations

1470 United States sites

350 Spain sites

280 Belgium sites

210 Brazil sites

210 Colombia sites

210 Germany sites

210 India sites

210 Italy sites

210 United Kingdom sites

140 Canada sites

140 Lebanon sites

140 Turkey sites

70 Oman sites

70 Switzerland sites

70 France sites

Age

6 Months - 17 Years

Phase

Phase 2

LEARN MORE